”1 in 78 Women might develop ovarian cancer in their lifetime.
XENA® is a blood-based liquid biopsy test for the early detection of ovarian cancer.
XENA® only requires whole blood collected from the arm.
Greatly enhanced accuracy over the current CA125 screening test.
Reduces the need for unnecessary invasive biopsies.
Partnerships are vital for continued medical advancements. We constantly seek collaborators to:
1 Science Park Road
#04-10 The Capricorn
Singapore 117528
1 Science Park Road
#04-10 The Capricorn
Singapore 117528
Please note that the contents of this website are for corporate and non-commercial information purposes only and are provided on the understanding that no surgical or medical advice or recommendation is being rendered. Please refer to our website Terms of Use. The content of this site may not be construed as advertisements for any product or service that INEX or any of its subsidiary companies offers.
© 2025 INEX INNOVATE PRIVATE LIMITED. ALL RIGHTS RESERVED. 0009-0302-00.
A simple sample collection using the common HPV swab is taken and the DNA is extracted. The extracted DNA undergoes bisulfite conversion before an accurate method of screening through real-time PCR analyses. The bisulfite conversion functions by converting unmethylated Cytosine nucleotides to Uracil, which is then converted to Thymine by PCR. Conversely, the methylation mark protects the methylated Cytosine nucleotides from being converted to Uracil.
